548773-13-3 Usage
Uses
Used in Pharmaceutical Industry:
2-amino-4,6-dimethylpyrimidine-5-carboxylic acid is used as a building block for the synthesis of various drugs, contributing to the development of new therapeutic agents. Its presence in drug formulations is attributed to its ability to enhance the pharmacological properties of the final product.
Used as an Intermediate in Chemical Production:
In the chemical industry, 2-amino-4,6-dimethylpyrimidine-5-carboxylic acid is utilized as an intermediate in the production of other chemicals. Its role in chemical synthesis processes is crucial for creating a range of compounds with diverse applications.
Used in Research and Development:
2-amino-4,6-dimethylpyrimidine-5-carboxylic acid is employed in research settings to study its potential biological activities and therapeutic properties. Scientists are interested in exploring its interactions with biological systems and its potential to contribute to the discovery of new medicines and treatments.
Check Digit Verification of cas no
The CAS Registry Mumber 548773-13-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,4,8,7,7 and 3 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 548773-13:
(8*5)+(7*4)+(6*8)+(5*7)+(4*7)+(3*3)+(2*1)+(1*3)=193
193 % 10 = 3
So 548773-13-3 is a valid CAS Registry Number.
InChI:InChI=1S/C7H9N3O2/c1-3-5(6(11)12)4(2)10-7(8)9-3/h1-2H3,(H,11,12)(H2,8,9,10)
548773-13-3Relevant articles and documents
Oximino-piperidino-piperidine-based CCR5 antagonists. Part 2: Synthesis, SAR and biological evaluation of symmetrical heteroaryl carboxamides
Palani, Anandan,Shapiro, Sherry,Clader, John W.,Greenlee, William J.,Vice, Susan,McCombie, Stuart,Cox, Kathleen,Strizki, Julie,Baroudy, Bahige M.
, p. 709 - 712 (2007/10/03)
The synthesis, SAR and biological evaluation of symmetrical amide analogues of our clinical candidate SCH 351125 are described. A series of potent and orally bioavailable CCR5 antagonists containing symmetrical 2,6-dimethyl isonicotinamides and 2, 6-dimethyl pyrimidines amides were generated with enhanced affinity for the CCR5 receptor.
Piperazine-based CCR5 antagonists as HIV-1 inhibitors. III: Synthesis, antiviral and pharmacokinetic profiles of symmetrical heteroaryl carboxamides
McCombie, Stuart W.,Tagat, Jayaram R.,Vice, Susan F.,Lin, Sue-Ing,Steensma, Ruo,Palani, Anandan,Neustadt, Bernard R.,Baroudy, Bahige M.,Strizki, Julie M.,Endres, Michael,Cox, Kathleen,Dan, Niya,Chou, Chuan-Chu
, p. 567 - 571 (2007/10/03)
The unsymmetrical nicotinamide-N-oxide moiety in compound 1 was replaced with symmetrical isonicotinamides as well as 4,6-dimethyl pyrimidine-5-carboxamides. Compound 16 from the latter set reduced the number of rotamers, improved potency of inhibiting UIV entry, slightly diminished the affinity for the muscarine receptors and showed very good oral absorption.
